Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014 Post published:September 14, 2022 Post category:Press Release
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries Post published:September 7, 2022 Post category:Press Release
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds Post published:August 31, 2022 Post category:Press Release
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Post published:August 30, 2022 Post category:Press Release
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Post published:August 9, 2022 Post category:Press Release
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders Post published:July 7, 2022 Post category:Press Release
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation Post published:June 29, 2022 Post category:Press Release
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin Post published:June 22, 2022 Post category:Press Release
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds Post published:April 19, 2022 Post category:Press Release
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions Post published:February 17, 2022 Post category:Press Release